Cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults. Transthyretin familial amyloid polyneuropathy (TTR-FAP).

 

" /> Tafamidis meglumine drug interactions | Litt's Drug Eruption and Reaction Database

Tafamidis meglumine

  • TRADE NAME: Vyndaqel (FoldRx Pharmaceuticals)
  • INDICATIONS:

     

    Cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults. Transthyretin familial amyloid polyneuropathy (TTR-FAP).

     

  • CLASS: Transthyretin stabilizer
  • HALF-LIFE: 49 hours

FDA APPROVAL DATE: 05/03/2019

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Breast Cancer Resistance Protein inhibitors, Imatinib, Methotrexate, Rosuvastatin

PREGNANCY CATEGORY: N/A
Based on findings from animal studies, tafamidis may cause fetal harm when administered to a pregnant woman.

Our database has 5 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

GASTROINTESTINAL/HEPATIC
GENITOURINARY
RESPIRATORY
OTHER


Page last updated 09/03/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top